Taysha基因疗法公司：关键性Reveal试验及Aspire试验给药完成预计于2026年第二季度

美股速递01-06

Taysha基因疗法公司宣布，其关键性Reveal临床试验以及Aspire试验的给药阶段预计将于2026年第二季度完成。这一进展标志着公司在推进其基因疗法研发项目方面取得了重要里程碑。

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/1178054298?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-01-06 21:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1178054298","market":"us","top_or_hot":-1,"title":"Taysha基因疗法公司：关键性Reveal试验及Aspire试验给药完成预计于2026年第二季度","media":"美股速递","content":"<p>Taysha基因疗法公司宣布，其关键性Reveal临床试验以及Aspire试验的给药阶段预计将于2026年第二季度完成。这一进展标志着公司在推进其基因疗法研发项目方面取得了重要里程碑。</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Taysha基因疗法公司：关键性Reveal试验及Aspire试验给药完成预计于2026年第二季度</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTaysha基因疗法公司：关键性Reveal试验及Aspire试验给药完成预计于2026年第二季度\n</h2>\n\n<h4 class=\"meta\">\n\n2026-01-06 21:02 北京时间&nbsp;&nbsp;&nbsp;<strong>美股速递</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Taysha基因疗法公司宣布，其关键性Reveal临床试验以及Aspire试验的给药阶段预计将于2026年第二季度完成。这一进展标志着公司在推进其基因疗法研发项目方面取得了重要里程碑。</p>\n\n<a href=\"\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TSHA","symbol_name":"Taysha Gene Therapies, Inc.","start_time":0,"source_url":"","article_id":"1178054298","we_media_id":"1004306016","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1178054298","pubTimestamp":1767704564,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"美股速递","introduction":"全球快讯第一时间播报","home_visible":1,"id":"1004306016","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Taysha基因疗法公司宣布，其关键性Reveal临床试验以及Aspire试验的给药阶段预计将于2026年第二季度完成。这一进展标志着公司在推进其基因疗法研发项目方面取得了重要里程碑。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"TSHA":"Taysha Gene Therapies, Inc.","BK4139":"生物科技"},"translate_title":"Taysha Gene Therapy Company: Dosing completion of pivotal Reveal trial and Aspire trial is expected in the second quarter of 2026","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TSHA":1},"content_text":"Taysha基因疗法公司宣布，其关键性Reveal临床试验以及Aspire试验的给药阶段预计将于2026年第二季度完成。这一进展标志着公司在推进其基因疗法研发项目方面取得了重要里程碑。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":true,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1178054298","isCrawlerRequest":true}